Salvianolic acid B exerts its anti-tumor immunity by targeting USP2 and reducing the PD-L1 level
10.16438/j.0513-4870.2023-0027
- VernacularTitle:靶向USP2下调PD-L1表达的丹酚酸B抗肿瘤免疫作用研究
- Author:
Ze-an KUANG
1
;
Jing-wen DONG
1
;
Cui-cui SUN
1
;
Ming-xiao YIN
1
;
Lu LIU
2
;
Hong-bin DENG
1
;
Xiao-jia LIU
3
;
Yan-chun FENG
4
Author Information
1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Qingdao Women and Children′s Hospital, Qingdao 266034, China
3. Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Beijing 100050, China
4. National Institutes for Food and Drug Control, Beijing 102629, China
- Publication Type:Research Article
- Keywords:
programmed cell death ligand 1;
ubiquitin carboxyl-terminal hydrolase 2;
anti-tumor immunity;
salvianolic acid B;
immune checkpoint inhibitor;
eubiquitination
- From:
Acta Pharmaceutica Sinica
2023;57(4):954-962
- CountryChina
- Language:Chinese
-
Abstract:
With the development of small-molecule immunotherapy drugs, its combination with the programmed cell death ligand 1/programmed cell death protein 1 (PD-L1/PD-1) antibodies would provide a new opportunity for cancer treatment. Therefore, targeting PD-L1/PD-1 axis by small-molecule drug is an attractive approach to enhance antitumor immunity and considered as the next generation of tumor immunotherapy. In the present study, we investigated the anti-tumor role of salvianolic acid B (SAB) by regulating the PD-L1 level in tumors. Changes of total PD-L1 and membrane PD-L1 levels were determined by Western blot, flow cytometry and PD-1/PD-L1 interaction assays. The expression of mRNA level of PD-L1 was detected by real-time PCR. The cytotoxicity of activated peripheral blood mononuclear cell (PBMC) cells toward co-cultured tumor cells was measured by cell impedance assay and crystal violet experiment. Surface plasma resonance technique was used to analyze the direct interaction between SAB and ubiquitin carboxyl-terminal hydrolase 2 (USP2). The antitumor effect of SAB in vivo was examined by C57BL/6 mice bearing MC38 xenograft tumor (all animal experiments were conducted in accordance with the Animal Ethics Committee of the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences). Western blot and flow cytometry assay showed that SAB can significantly downregulate the abundance of PD-L1 in RKO and PC3 cells in dose- and time-dependent manner. PD-1/PD-L1 binding assay revealed that SAB reduces the binding of tumor cells to recombinant PD-1 protein. Mechanism studies revealed that SAB can bind directly to USP2 protein and inhibit its activity, thus promote the ubiquitin-proteasome pathway degradation of PD-L1 proteins. In addition, Cell impedance and crystal violet staining indicated that SAB enhances the killing activity of co-cultured PBMC cells toward tumor cells. MC38 tumor transplanted mouse experiments revealed that SAB treatment displayed significant suppression in the growth of MC38 tumor xenografts in C57BL/6 mice with an inhibition rate of 63.2% at 20 mg·kg-1. Our results demonstrate that SAB exerts its anti-tumor activity by direct binding and inhibiting the activity of USP2 and reducing the PD-L1 level. Our study provides an important material basis and scientific basis for the potential application of SAB in tumor immunotherapy drug targeting USP2-PD-L1 axis.
